Arginine Therapy for Sickle Cell Disease Acute Pain Episodes

In a phase 3 randomized clinical trial of children and young adults with sickle cell disease acute pain episodes, intravenous arginine did not shorten time to crisis resolution compared with placebo. No significant differences were observed in opioid use, pain scores, patient-reported outcomes, or safety events. The trial was stopped early for futility.

Corresponding Author: Claudia R. Morris, MD, Emory University School of Medicine, 1760 Haygood Dr NE, W458, Atlanta, GA 30322 (claudia.r.morris@emory.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.